Do SGLT2i and DPP-4i Differ in Hematologic Malignancy Risk? Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about Do SGLT2i and DPP-4i Differ in Hematologic Malignancy Risk?
Gout Medication Use Lower Among T2DM Patients Using SGLT2 Inhibitors Tags GLP-1 agonists DPP-4 inhibitors SGLT-2 Inhibitor Read more about Gout Medication Use Lower Among T2DM Patients Using SGLT2 Inhibitors
Rheumatoid Arthritis Risk Lower Among DPP-4 Inhibitor Users Tags DPP-4 inhibitors Read more about Rheumatoid Arthritis Risk Lower Among DPP-4 Inhibitor Users
GLP-1-Based Therapies Show Distinct CV and Renal Effects in T2DM Tags Coronary artery disease Myocardial infarction GLP-1 agonists DPP-4 inhibitors Read more about GLP-1-Based Therapies Show Distinct CV and Renal Effects in T2DM
GLP-1 RAs Show Lower Mortality in RA With Type 2 Diabetes Tags Diabetic Nephropathy Coronary artery disease Myocardial infarction GLP-1 agonists DPP-4 inhibitors Read more about GLP-1 RAs Show Lower Mortality in RA With Type 2 Diabetes
Recurrent Ischemic Stroke Lower With SGLT2i in T2DM Tags DPP-4 inhibitors SGLT-2 Inhibitor Stroke Read more about Recurrent Ischemic Stroke Lower With SGLT2i in T2DM
OAC Risk Similar With SGLT2i and DPP4i in T2DM Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about OAC Risk Similar With SGLT2i and DPP4i in T2DM
GLP-1 RAs Show Greater HbA1c Improvement vs DPP-4 Inhibitors Tags DPP-4 inhibitors GLP-1 agonists hBA1c Read more about GLP-1 RAs Show Greater HbA1c Improvement vs DPP-4 Inhibitors
Fixed-Dose Empagliflozin/Linagliptin Shows Superior HbA1c Reduction with Metformin Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about Fixed-Dose Empagliflozin/Linagliptin Shows Superior HbA1c Reduction with Metformin